QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Unveils Development Strategy for PCaTest, Nears Close of Proposed ProstaGene Asset Acquisition
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing innovative treatments for multiple therapeutic indications, this morning detailed its strategy for completing the development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene. Following the completion of its previously announced proposed acquisition of assets from ProstaGene, which is expected to close during the fourth quarter of 2018, CytoDyn intends to initiate a clinical study aimed at further demonstrating the superiority of the PCaTest, as compared with current genetic tests, in predicting outcomes of individuals with prostate cancer. Per the update, results are expected to be available within…